Antihypertensive drugs and risk of COVID-19?
- 26 March 2020
- journal article
- letter
- Published by Elsevier BV in The Lancet. Respiratory Medicine
- Vol. 8 (5), e30-e31
- https://doi.org/10.1016/s2213-2600(20)30153-3
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?The Lancet Respiratory Medicine, 2020
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, ChinaJAMA, 2020
- Angiotensin receptor blockers as tentative SARS‐CoV‐2 therapeuticsDrug Development Research, 2020
- Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery diseasePLOS ONE, 2018
- Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodellingEP Europace, 2016
- Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infectionsNature Communications, 2014
- Lessons from SARS: control of acute lung failure by the SARS receptor ACE2Journal of Molecular Medicine, 2006
- A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injuryNature Medicine, 2005
- Angiotensin-converting enzyme 2 protects from severe acute lung failureNature, 2005
- Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirusNature, 2003